SCHEMBL2091316

SCHEMBL2091316

[O]C(=O)N(c1ccccc1)c1cccc(Cl)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.44
TSHR P16473 2/20 0.43
KMT2A Q03164 5/20 0.42
ALDH1A1 P00352 3/20 0.42
POLB P06746 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
HTT P42858 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.41
CACNA2D1 P54289 1/20 0.39
CACNA1B Q00975 1/20 0.39
CACNB1 Q02641 1/20 0.39
CACNA1C Q13936 1/20 0.39
MEN1 O00255 3/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 3/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2091321 0.88 NPSR1 (0.45) NPSR1TSHRKMT2AALDH1A1POLB
SCHEMBL2092882 0.87 NPSR1 (0.48) NPSR1KMT2AALDH1A1POLBNPC1
SCHEMBL2092002 0.83 KMT2A (0.42) NPSR1TSHRKMT2AALDH1A1POLB
SCHEMBL27296911 0.83 NPSR1 (0.46) NPSR1TSHRKMT2AALDH1A1POLB
SCHEMBL2089002 0.81 ATM (0.40) NPSR1TSHRKMT2AALDH1A1POLB
SCHEMBL2089007 0.81 PTGIR (0.41) NPSR1TSHRKMT2AALDH1A1POLB
SCHEMBL2097499 0.80 NPSR1 (0.48) NPSR1TSHRKMT2AALDH1A1POLB
SCHEMBL6003085 0.77 PTGIR (0.39) NPSR1TSHRKMT2AALDH1A1POLB
SCHEMBL2095449 0.75 NPSR1 (0.47) NPSR1TSHRKMT2AALDH1A1POLB
SCHEMBL2095799 0.75 FSCN1 (0.47) NPSR1TSHRKMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 NPSR1 202/4885TSHR 162/4885KMT2A 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.